CIK: 0001823138 · Show all filings
Period: Q1 2024 (← Previous) (Next →)
Filing Date: May 15, 2024
Total Value ($000): $510,543 (96.7% shares, 3.3% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | INDIVIOR PLC | 13,251,002 | $283,836 | 55.6% | $23.71 | — | ORD | G4766E116 |
| ROIV | ROIVANT SCIENCES LTD | 7,930,349 | $83,586 | 16.4% | $5.52 | +95.4% | SHS | G76279101 |
| ABUS | ARBUTUS BIOPHARMA CORP | 7,841,927 | $20,232 | 4.0% | $2.63 | -1.4% | COM | 03879J100 |
| IMVT | IMMUNOVANT INC | 541,295 | $17,489 | 3.4% | $31.39 | +16.2% | COM | 45258J102 |
| — | ESPERION THERAPEUTICS INC NE | 20,315,000 | $16,887 | 3.3% | $0.59 | — | NOTE 4.000%11/1 | 29664WAB1 |
| META | META PLATFORMS INC | 31,958 | $15,518 | 3.0% | $259.39 | +70.9% | CL A | 30303M102 |
| VST | VISTRA CORP | 197,353 | $13,746 | 2.7% | $48.74 | 0.0% | COM | 92840M102 |
| CORZ | CORE SCIENTIFIC INC NEW | 3,830,967 | $13,562 | 2.7% | $3.47 | 0.0% | COM | 21874A106 |
| ESPR | ESPERION THERAPEUTICS INC NE | 4,165,657 | $11,164 | 2.2% | $1.43 | +70.2% | COM | 29664W105 |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | 809,332 | $8,020 | 1.6% | $7.46 | 0.0% | COM | 03969K108 |
| SONO | SONOS INC | 403,653 | $7,694 | 1.5% | $17.03 | +4.1% | COM | 83570H108 |
| — | AVADEL PHARMACEUTICALS PLC | 318,240 | $5,375 | 1.1% | $16.89 | — | SPONSORED ADR | 05337M104 |
| OMEX | ODYSSEY MARINE EXPL INC | 1,237,615 | $4,715 | 0.9% | $5.35 | -16.9% | COM NEW | 676118201 |
| GOOGL | ALPHABET INC | 24,371 | $3,678 | 0.7% | $141.98 | 0.0% | CAP STK CL A | 02079K305 |
| SHC | SOTERA HEALTH CO | 300,000 | $3,603 | 0.7% | $14.88 | 0.0% | COM | 83601L102 |
| CORZZ | CORE SCIENTIFIC INC NEW | 233,540 | $563 | 0.1% | $2.41 | — | *W EXP 01/23/202 | 21874A130 |
| — | TOURMALINE BIO INC | 21,891 | $501 | 0.1% | $22.90 | — | COM | 89157D105 |
| CORZW | CORE SCIENTIFIC INC NEW | 280,248 | $373 | 0.1% | $1.33 | — | *W EXP 01/23/202 | 21874A114 |